VP & Counsel, Editas Medicine
Gary Sclar is VP & Counsel at Editas Medicine and is the lead attorney for business development and research & development transactions. Prior to Editas he was Deputy General Counsel for Apellis Pharmaceuticals with responsibilities for research collaborations, business development, investigator initiated and clinical trials, digital health, mergers & acquisitions, and general corporate matters, and was Vice President of Innovations at the Dana-Farber Cancer Institute where he led licensing, strategic partnering, royalty monetizations, and new company creation. He was Chief Strategy Officer for MedMetrics Health Partners and Public Sector Partners and has had varying roles in technology licensing at Northeastern University, Brigham and Women’s Hospital, and the University of Massachusetts Medical School. Early in his career he directed labs at Washington University School of Medicine and the Jackson Laboratory specializing in nuclear transplantation and the generation of transgenic and embryonic stem cell knock-out models. Gary is admitted to the Massachusetts Bar and the United States District Court in Massachusetts and enjoys running, surfing, and playing renaissance music on the mandolin.